Soligenix, Inc. Common Stock (SNGX) Stock Price

SNGXStock

$0.35−77.22%52W

Market Cap$7.69M

P/E—

PEG Ratio—

Div yield—

Beta2.14

SNGX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-79.20%

Price vs S&P 500 (4W)-3.76%

VGM Score37.13

Book Value / Share (Quarterly)$0.31

P/TBV (Annual)10.22x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-47.39%

Cash Flow / Share (Quarterly)$-0.45

Price vs S&P 500 (YTD)-85.58%

Gross Margin (TTM)8.75%

Net Profit Margin (TTM)-1424.53%

EPS (TTM)$-1.27

10-Day Avg Trading Volume0.15M

EPS Excl Extra (TTM)$-1.27

Revenue Growth (5Y)-51.89%

EPS (Annual)$-2.14

ROI (Annual)-209.37%

Gross Margin (Annual)0.00%

Net Profit Margin (5Y Avg)-2277.89%

Cash / Share (Quarterly)$0.45

ROA (Last FY)-119.98%

EBITD / Share (TTM)$-1.08

ROE (5Y Avg)-248.72%

Operating Margin (TTM)-1574.25%

Cash Flow / Share (Annual)$-1.02

P/B Ratio1.16x

P/B Ratio (Quarterly)0.88x

Net Income / Employee (Annual)$-852,300

EV / Revenue (TTM)-4.30x

Net Interest Coverage (TTM)-1725.75x

ROA (TTM)-107.92%

EV / EBITDA (TTM)-1.76x

EPS Incl Extra (Annual)$-2.14

Current Ratio (Annual)2.39x

Quick Ratio (Quarterly)2.67x

3-Month Avg Trading Volume0.35M

52-Week Price Return-77.22%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$1.83

P/S Ratio (Annual)64.38x

Asset Turnover (Annual)0.01x

52-Week High$1.76

Operating Margin (5Y Avg)-2540.96%

EPS Excl Extra (Annual)$-2.14

CapEx CAGR (5Y)-10.08%

Tangible BV CAGR (5Y)6.73%

26-Week Price Return-69.30%

Quick Ratio (Annual)2.15x

13-Week Price Return-1.64%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)2.77x

Enterprise Value$-2.13M

Revenue / Share Growth (5Y)-54.25%

Asset Turnover (TTM)0.05x

Book Value / Share Growth (5Y)-12.22%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-7267.90%

Cash / Share (Annual)$0.79

3-Month Return Std Dev37.64%

Gross Margin (5Y Avg)17.76%

Net Income / Employee (TTM)$-787,700

ROE (Last FY)-209.37%

Net Interest Coverage (Annual)-14.55x

EPS Basic Excl Extra (Annual)$-2.14

P/FCF (TTM)2.80x

Receivables Turnover (TTM)1.39x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.27

Receivables Turnover (Annual)1.39x

ROI (TTM)-181.02%

P/S Ratio (TTM)15.55x

Pretax Margin (5Y Avg)-2441.11%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$1.83

Price vs S&P 500 (52W)-92.75%

Year-to-Date Return-73.65%

5-Day Price Return0.40%

EPS Normalized (Annual)$-2.14

ROA (5Y Avg)-83.64%

Net Profit Margin (Annual)-6925.17%

Month-to-Date Return-2.46%

Cash Flow / Share (TTM)$-1.38

EBITD / Share (Annual)$-2.28

Operating Margin (Annual)-7907.77%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-130.65%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.27

P/TBV (Quarterly)10.22x

P/B Ratio (Annual)2.55x

Inventory Turnover (TTM)29.64x

Pretax Margin (TTM)-1547.28%

Book Value / Share (Annual)$0.52

Price vs S&P 500 (13W)-4.33%

Beta2.14x

Revenue / Share (TTM)$0.00

ROE (TTM)-181.02%

52-Week Low$0.28

vGradeB

gGradeF

mGradeC

vgmGradeD

SNGX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 7, 2026	-$0.09	-$0.13	-42.44%(-$0.04)
Q1 2026	May 8, 2026	-$0.24	-$0.28	-16.67%(-$0.04)
Q3 2025	Nov 7, 2025	-$0.48	-$0.58	-20.83%(-$0.10)
Q2 2025	Aug 14, 2025	-$1.05	-$0.82	+21.90%(+$0.23)

SNGX Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.14

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
SNGXSoligenix, Inc. Common Stock	B	F	C	15.6x	—	8.8%	—	$0.35
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Soligenix, Inc. Common Stock

Soligenix is a biopharmaceutical company developing therapeutics and vaccines for rare diseases and public health threats with unmet medical needs. Operating through Specialized BioTherapeutics and Public Health Solutions segments, the company generates primary revenues from Public Health Solutions, including RiVax (a ricin toxin vaccine candidate), SGX943 (for antibiotic-resistant and emerging infectious diseases), and vaccine research programs targeting Ebola, Marburg, and SARS-CoV-2.